title: Describing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study.
abstract: Improved understanding of the pattern of cognitive decline in Alzheimer's disease (AD) would be useful to assist primary care physicians in explaining AD progression to patients and caregivers.
  
  
  
  To identify the sequence in which cognitive abilities decline in community-dwelling patients with AD.
  
  
  
  Baseline data were analyzed from 1,495 patients diagnosed with probable AD and a Mini-Mental State Examination (MMSE) score ≤ 26 enrolled in the 18-month observational GERAS study. Proportional odds logistic regression models were applied to model MMSE subscores (orientation, registration, attention and concentration, recall, language, and drawing) and the corresponding subscores of the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), using MMSE total score as the index of disease progression. Probabilities of impairment start and full impairment were estimated at each MMSE total score level.
  
  
  
  From the estimated probabilities for each MMSE subscore as a function of the MMSE total score, the first aspect of cognition to start being impaired was recall, followed by orientation in time, attention and concentration, orientation in place, language, drawing, and registration. For full impairment in subscores, the sequence was recall, drawing, attention and concentration, orientation in time, orientation in place, registration, and language. The sequence of cognitive decline for the corresponding ADAS-cog subscores was remarkably consistent with this pattern.
  
  
  
  The sequence of cognitive decline in AD can be visualized in an animation using probability estimates for key aspects of cognition. This might be useful for clinicians to set expectations on disease progression for patients and caregivers.
authors.affiliation: Lilly Deutschland GmbH, Bad Homburg, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Henneges
authors.affiliation: Eli Lilly and Company Limited, Lilly Research Centre, Windlesham, UK.
authors.forename: Catherine
authors.initials: C
authors.lastname: Reed
authors.affiliation: Eli Lilly & Co., Indianapolis, USA.
authors.forename: Yun-Fei
authors.initials: YF
authors.lastname: Chen
authors.affiliation: Lilly Italia S.p.A. Sesto Fiorentino, (FI), Italy.
authors.forename: Grazia
authors.initials: G
authors.lastname: Dell'Agnello
authors.affiliation: Lilly Deutschland GmbH, Bad Homburg, Germany.
authors.forename: Jeremie
authors.initials: J
authors.lastname: Lebrec
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease; D017028:Caregivers / Q000523:psychology; D003072:Cognition Disorders / Q000209:etiology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D009483:Neuropsychological Tests; D016017:Odds Ratio
keywords: Alzheimer’s disease; cognition; disease progression; observational study